You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究下調阿里健康(00241.HK)目標價至16.5元 評級「買入」
阿里健康(00241.HK)截至9月底止六個月收入93.58億人民幣(下同),按年增加30.7%。錄得虧損2.32億元,相比對上財年同期純利2.83億元盈轉虧。匯豐研究發表報告,阿里健康中期業績符合預期,不過下調其收入預測,將其目標價由18.5元下調至16.5元,維持「買入」評級。 匯豐研究根據管理層的指引,將2022財下半年的收入增長預測從之前的37%下調至33%,2022至2024財年的複合年增長率從之前的42%下調至33%;並將收支平衡時間預測由原先2023或2024財年,推遲到2025財年,主因下調集團平台業務(3P)及毛利率預測。 匯豐研究指,鑑於在線藥品銷售滲透率不斷加深,看好公司的長期增長前景,相信通過更廣泛地利用阿里巴巴(09988.HK)生態系統,可以使其在競爭中脫穎而出。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account